Confirmation

Are you sure you want to sign out?

Sign Out Cancel

Clinical Practice Guidelines
test root item
New Drug Monograph
title -v1234567-Novtest
BCEHS Handbook FAQ
About BCEHS Handbook
Licence Level Filtering

PCP ACP CCP EMR DISPATCH

Download PDF Open All

PhenyLEPHRine

Classification

Sympathomimetic

Indications

ACP: Maintenance of blood pressure in acute hypotensive states, or shock following adequate fluid volume replacement

Contraindications

Known hypersensitivity or allergy to phenyLEPHRine
Hypersensitivity to sulfites (contained in the product preparation)
Severe hypertension or ventricular tachycardia
Pheochromocytoma

Adult dosages

ACP: Maintenance of blood pressure in acute hypotensive states, or shock following adequate fluid volume replacement

100 mcg IV slow push every 2-5 minutes to maximum of 500 mcg
Administer dose over 20-30 seconds
If higher doses are required, consult with CliniCall

Pediatric Considerations And Dosing

Not authorized. Consider the use of push-dose epinephrine in these patients.

Mechanism Of Action

Agonizes alpha-adrenergic receptors producing arterial vasoconstriction

Pharmocokinetics

Intravenous:

Onset: rapid
Duration: 15-20 minutes

Adverse Effects

Headache
Nervousness
Reflex bradycardia
Nausea and vomiting
Paresthesia
May produce significant peripheral or visceral vasoconstriction

Warning And Precautions

Exercise caution when administering phenyLEPHRine to patients with bradycardia, incomplete AV block, or other underlying cardiovascular disease.

PhenyLEPHRine carries a significant risk of sloughing and tissue necrosis if extravasation occurs. Ensure administration line is patent and free-flowing.

Rapid IV administration of phenyLEPHRine may result in development of premature ventricular contractions, ventricular tachycardia, and hypertension.